Cerity Partners LLC Reduces Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Cerity Partners LLC reduced its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 47.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,359 shares of the biopharmaceutical company's stock after selling 15,537 shares during the period. Cerity Partners LLC's holdings in Royalty Pharma were worth $459,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in RPRX. Brooklyn Investment Group increased its stake in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares during the period. Allworth Financial LP grew its holdings in Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co increased its position in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,186 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 997 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Royalty Pharma currently has an average rating of "Buy" and an average price target of $42.50.

Royalty Pharma Price Performance

RPRX traded down $0.50 during midday trading on Wednesday, reaching $31.69. 4,185,299 shares of the company's stock were exchanged, compared to its average volume of 3,251,666. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The stock has a market capitalization of $18.27 billion, a PE ratio of 21.86, a P/E/G ratio of 2.31 and a beta of 0.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The business's 50-day moving average price is $32.54 and its 200 day moving average price is $29.36.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.78%. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.